To scroll text in this page
Strengthening drug discovery capabilities and accelerating exploratory research
To deliver a new drug to our patients as soon as possible, we are centering our drug creation efforts in the five strategic focus therapeutic fields of urology, immunology and infectious diseases, oncology, neuroscience, and DM complications and metabolic diseases. In addition to leveraging our expertise in drug discovery research, centered on low molecules, we are consolidating the technology platforms necessary to more efficiently develop antibody pharmaceuticals. As part of these efforts, Agensys, Inc., a U.S.-based biotechnology company, joined Astellas in December 2007. Then, in September 2008, we completed construction of a new research building at Tsukuba Research Center (Miyukigaoka). This research center, with drug discovery research facilities among the most advanced in Japan, serves as the center of our global research network, which also includes research bases in the U.S. and Europe. We have created this network to improve the speed and quality of our drug discovery research.